Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell
transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion.
Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients.
the study is to evaluate the safety and efficacy of interferon for the intervention of
molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell
transplantation (allo-SCT)